Developmental biology of thrombopoietin in the human fetus and neonate

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 91, Issue 438, 2002, Pages 54-65

  Dame, C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

C mpl; Fetus; Neonate; Thrombocytopenia; Thrombopoietin

Indexed keywords

THROMBOPOIETIN;

BONE MARROW; CONFERENCE PAPER; FETUS; FETUS DEVELOPMENT; FETUS HYPOXIA; GENE EXPRESSION; GENETIC DISORDER; HEMATOPOIESIS; HORMONE SYNTHESIS; HUMAN; IMMUNOPATHOLOGY; INFECTION; INTRAUTERINE GROWTH RETARDATION; LIVER DISEASE; MATERNAL DIABETES MELLITUS; MATERNAL HYPERTENSION; MEGAKARYOPOIESIS; MOLECULAR BIOLOGY; MYELOPROLIFERATIVE DISORDER; NEWBORN; NEWBORN HEMOLYTIC DISEASE; OSTEOPOROSIS; PERINATAL DEVELOPMENT; PRIORITY JOURNAL; REGULATORY MECHANISM; STEM CELL; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TRISOMY 21;

EID: 0036429692     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2002.tb02906.x     Document Type: Conference Paper

References (142)

1. Kelemen E, Calvo W, Fliedner TM. Atlas of Human Haematopoietic Development. New York: Springer; 1979
2. Allen Graeve JL, de Alarcon PA. Megakaryocytopoiesis in the human fetus. Arch Dis Child 1989; 64: 481-4
3. Ma DC, Sun YH, Chang KZ, Zuo W. Developmental change of megakaryocyte maturation and DNA ploidy in human fetus. Eur J Haematol 1996; 57: 121-7
4. Hegyi E, Nakazawa M, Debili N, Navarro S, Katz A, Breton-Gorius J, et al. Developmental changes in human megakaryocyte ploidy. Exp Hematol 1991; 19: 87-94
5. Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986; 20: 342-6
6. Forestier F, Daffos F, Catherine N, Renard M, Andreux JP. Developmental hematopoiesis in normal human fetal blood. Blood 1991; 77: 2360-3
7. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988; 319: 142-5
8. Burrows RF, Kelton JG. Thrombocytopenia ar delivery: A prospective survey of 6715 deliveries. Am J Obstet Gynecol 1990; 162: 731-4
9. Sainio S, Jarvenpaa AL, Renlund M, Riikonen S, Teramo K, Kekomaki R. Thrombocytopenia in term infants: A population-based study. Obstet Gynecol 2000; 95: 441-6
10. Mehta P, Vasa R, Neumann L, Karpatkin M. Thrombocytopenia in tine high-risk infant. J Pediatr 1980; 97: 791-4
11. Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter C. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986; 108: 749-55
12. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: Incidence, serological and clinical observations. Am J Perinatol 1997; 14: 415-8
13. Metcalf D. Blood. Thrombopoietin - At last. Nature 1994; 369: 519-20
14. De Sauvage FJ. Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-8
15. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-8
16. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-24
17. Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994; 353: 57-61
18. Ballmaier M, Schulze H, Strauss G, Cherkaoui K, Wittner N, Lynen S, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: Elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90: 612-9
19. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-46
20. Kaushansky K. CAMT: New findings and new questions. Blood 2001; 97: 1
21. Roberts IA, Murray NA. Neonatal thrombocytopenia: New insights into pathogenesis and implications for clinical management. Curr Opin Pediatr 2001; 13: 16-21
22. Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, et al. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice. Exp Hematol 1996; 24: 1238-46
23. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: A pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002; 13: 61-73
24. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol Basel 1958; 20: 350-5
25. Wendling F, Varlet P, Charon M, Tambourin P. MPLV: A retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 1986; 149: 242-6
26. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63: 1137-47
27. Vigon I, Mornon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89: 5640-4
28. Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, et al. Purification and characterization of thrombopoietin [published erratum appears in J Biochem (Tokyo) 1996; I19: 208]. J Biochem (Tokyo) 1995; 118: 229-36
29. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8
30. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-71
31. De Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183: 651-6
32. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, et al. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 1994; 84: 2422-30
33. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-4
34. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85: 391-401
35. Angchaisuksiri P, Carlson PL, Dessypris EN. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol 1996; 93: 13-7
36. Choi ES, Hokom M, Bartley T, Li YS, Ohashi H, Kato T, et al. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem Cells 1995; 13: 317-22
37. Vitrat N, Cohen-Solal K, Pique C, Le Couedic JP, Norol F, Larsen AK, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 1998; 91: 3711-23
38. Carow CE, Fox NE, Kaushansky K. Kinetics of endomitosis in primary murine megakaryocytes. J Cell Physiol 2001; 188: 291-303
39. Schipper LF, Brand A, Reniers NC, Melief CJ, Willemze R, Fibbe WE. Effects of thrombopoietin on the proliferation and differentiation of primitive and mature haemopoietic progenitor cells in cord blood. Br J Haematol 1998; 101: 425-35
40. Campagnoli C, Fisk N, Overton T, Bennett P, Watts T, Roberts I. Circulating hematopoietic progenitor cells in first trimester fetal blood. Blood 2000; 95: 1967-72
41. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998; 43: 148-51
42. Watts TL, Murray NA, Roberts IA. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999; 46: 28-32
43. Nishihira H, Toyoda Y, Miyazaki H, Kigasawa H, Ohsaki E. Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies. Br J Haematol 1996; 92: 23-8
44. Sola MC, Du Y, Hutson AD, Christensen RD. Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000; 110: 449-53
45. Mwamtemi HH, Higuchi T, Sawai N, Hidaka E, Koike K. Quantitative and qualitative differences in thrombopoietin-dependent hematopoietic progenitor development between cord blood and bone marrow. Transplantation 2000; 69: 1645-54
46. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86: 419-31
47. Debili N, Masse JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993; 82: 84-95
48. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996; 87: 2162-70
49. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-7
50. Birkmann J, Oez S, Smetak M, Kaiser G, Kappauf H, Gallmeier WM. Effects of recombinant human thrombopoietin alone and in combination with erythropoietin and early-acting cytokines on human mobilized purified CD34+ progenitor cells cultured in serum-depleted medium. Stem Cells 1997; 15: 18-32
51. Scott CL, Robb L, Mansfield R, Alexander WS, Begley CG. Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice. Exp Hematol 2000; 28: 1001-7
52. Chen Q, Solar G, Eaton DL, de Sauvage FJ. IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Stem Cells 1998; 16 Suppl 2: 31-6
53. Gainsford T, Roberts AW, Kimura S, Metcalf D, Dranoff G, Mulligan RC, et al. Cytokine production and function in c-mpl-deficient mice: No physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood 1998; 91: 2745-52
54. Gainsford T, Nandurkar H, Metcalf D, Robb L, Begley CG, Alexander WS. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000; 95: 528-34
55. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 1998; 95: 1195-200
56. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92: 4-10
57. Ritchie A, Vadhan-Raj S, Broxmeyer HE. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells 1996; 14: 330-6
58. Ritchie A, Gotoh A, Gaddy J, Braun SE, Broxmeyer HE. Thrombopoietin upregulates the promoter conformation of p53 in a proliferation-independent manner coincident with a decreased expression of Bax: Potential mechanisms for survival enhancing effects. Blood 1997; 90: 4394-402
59. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96: 1683-7
60. Sawai N, Koike K, Mwamtemi HH, Ito S, Kurokawa Y, Sakashita K, et al. Thrombopoietin enhances neutrophil production by bone marrow hematopoietic progenitors with the aid of stem cell factor in congenital neutropenia. J Leukoc Biol 2000; 68: 137-43
61. Liu W, Wang M, Tang DC, Ding I, Rodgers GP. Thrombopoietin has a differentiative effect on late-stage human erythropoiesis. Br J Haematol 1999; 105: 459-69
62. Komatsu N, Kirito K, Shimizu R, Kunitama M, Yamada M, Uchida M, et al. In vitro development of erythroid and megakaryocytic cells from a UT-7 subline, UT-7/GM. Blood 1997; 89: 4021-33
63. Zauli G, Bassini A, Vitale M, Gibellini D, Celeghini C, Caramelli E, et al. Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 1997; 89: 883-95
64. Cui L, Ramsfjell V, Borge OJ, Veiby OP, Lok S, Jacobsen SE. Thrombopoietin promotes adhesion of primitive human hemopoietic cells to fibronectin and vascular cell adhesion molecule-1: Role of activation of very late antigen (VLA)-4 and VLA-5. J Immunol 1997; 159: 1961-9
65. Hunt P, Li YS, Nichol JL, Hokom MM, Bogenberger JM, Swift SE, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995; 86: 540-7
66. Linden HM, Kaushansky K. The glycan domain of thrombopoietin enhances its secretion. Biochemistry 2000; 39: 3044-51
67. Foster D, Hunt P. The biological significance of truncated and full-length forms of mpl ligand. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, editors. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology. Totowa, NJ: Humana Press; 1997. p. 203-14
68. Hoffman RC, Andersen H, Walker K, Krakover JD, Patel S, Stamm MR, et al. Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246. Biochemistry 1996; 35: 14849-61
69. Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ, Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981-8
70. Chang MS, McNinch J, Basu R, Shutter J, Hsu RY, Perkins C, et al. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Biol Chem 1995; 270: 511-4
71. Sasaki Y, Takahashi T, Miyazaki H, Matsumoto A, Kato T, Nakamura K, et al. Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 1999; 94: 1952-60
72. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: Evidence against regulation ar the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-73
73. Muto T, Feese MD, Shimada Y, Kudou Y, Okamoto T, Ozawa T, et al. Functional analysis of the C-terminal region of recombinant human thrombopoietin. C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion. J Biol Chem 2000; 275: 12090-4
74. Li B, Pan H, Winkelmann JC, Dai W. Thrombopoietin and its alternatively spliced form are expressed in human amygdala and hippocampus. Blood 1996; 87: 5382-4
75. Sola MC, Juul SE, Meng YG, Garg S, Sims P, Calhoun DA, et al. Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. Early Hum Dev 1999; 53: 239-50
76. Wolber EM, Dame C, Fahnenstich H, Hofmann D, Bartmann P, Jelkmann W, et al. Expression of the thrombopoietin gene in human fetal and neonatal tissues. Blood 1999; 94: 97-105
77. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92: 3218-25
78. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89: 101-7
79. Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998; 16: 1-6
80. Cardier JE, Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: Evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood 1998; 91: 923-9
81. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-75
82. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-61
83. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578-84
84. Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000; 20: 499-506
85. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost 2001; 86: 1421-4
86. Yamashita K, Matsuoka H, Ochiai T, Matsushita R, Kubuki Y, Suzuki M, et al. Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers. J Gastroenterol Hepatol 2000; 15: 83-90
87. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720-5
88. Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-8
89. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, intemalization, stability and pharmacokinetics. Br J Haematol 1999; 106: 345-56
90. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-71
91. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30
92. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997; 77: 808-14
93. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996; 76: 156-60
94. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-6
95. Hsu HC, Tsai WH, Jiang ML, Ho CH, Hsu ML, Ho CK, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med 1999; 134: 392-7
96. Cerutti A, Custodi P, Mduranti, Cazzola M, Balduini CL. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clin Lab Haematol 1999; 21: 271-5
97. Ishiguro A, Suzuki Y, Mito M, Shimbo T, Matsubara K, Kato T, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 2002; 116: 612-8
98. Griesshammer M, Hornkohl A, Nichol JL, Hecht T, Raghavachar A, Heimpel H, et al. High levels of thrombopoietin in sera of patients with essential thrombocythemia: Cause or consequence of abnormal platelet production? Ann Hematol 1998; 77: 211-5
99. Kawasaki H, Nakano T, Kohdera U, Tahara T, Kato T, Kobayashi Y. Serum thrombopoietin concentration and peripheral platelet counts in essential thrombocythemia. Ann Hematol 2001; 80: 62-3
100. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 1998; 92: 1091-6
101. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 1999; 94: 1480-2
102. Cazzola M, Skoda RC. Translational pathophysiology: A novel molecular mechanism of human disease. Blood 2000; 95: 3280-8
103. Sungaran R, Chisholm OT, Markovic B, Khachigian LM, Tanaka Y, Chong BH. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood 2000; 95: 3094-101
104. Allen TD, Dexter TM. The essential cells of the hemopoietic microenvironment. Exp Hematol 1984; 12: 517-21
105. Walka MM, Sonntag J, Dudenhausen JW, Obladen M. Thrombopoietin concentration in umbilical cord blood of healthy term newborns is higher than in adult controls. Biol Neonate 1999; 75: 54-8
106. Sola MC, Calhoun DA, Hutson AD, Christensen RD. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999; 104: 90-2
107. Colarizi P, Fiorucci P, Caradonna A, Ficuccilli F, Mancuso M, Papoff P. Circulating thrombopoietin levels in neonates with infection. Acta Paediatr 1999; 88: 332-7
108. Ishiguro A, Nakahata T, Matsubara K, Hayashi Y, Kato T, Suzuki Y, et al. Age-related changes in thrombopoietin in children: Reference interval for serum thrombopoietin levels. Br J Haematol 1999; 106: 884-8
109. Ikeno K, Koike K, Takeshita A, Shinjo K, Higuchi T, Nakabayashi T, et al. Stressful delivery influences circulating thrombopoietin (TPO) levels in newborns: Possible role for cortisol in TPO-mpl binding. Early Hum Dev 2000; 58: 225-35
110. Albert TS, Meng YG, Simms P, Cohen RL, Phibbs RH. Thrombopoietin inthe thrombocytopenic term and preterm newborns. Pediatrics 2000; 105: 1286-91
111. Sainio S, Javela K, Kekomaki R, Teramo K. Thrombopoietin levels in cord blood plasma and amniotic fluid in fetuses with alloimmune thrombocytopenia and healthy controls. Br J Haematol 2000; 109: 330-5
112. Dame C, Cremer M, Ballmaier M, Bartmann P, Bald R, Schild RL, et al. Concentrations of thrombopoietin and interleukin-11 in the umbilical cord blood of patients with fetal alloimmune thrombocytopenia. Am J Perinatol 2001; 18: 335-44
113. Oygur N, Tunga M, Mumcu Y, Yesilipek A, Gura A, Coskun M, et al. Thrombopoietin levels of thrombocytopenic term and preterm newboms with infection. Am J Perinatol 2001; 18: 279-86
114. Matsubara K, Baba K, Nigami H, Harigaya H, Ishiguro A, Kato T, et al. Early elevation of serum thrombopoietin levels and subsequent thrombocytosis in healthy preterm infants. Br J Haematol 2001; 115: 963-8
115. Folman CC, von dem Borne AE, Rensink IH, Gerritsen W, van der Schoot CE, de Haas M, et al. Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay. Thromb Haemost 1997; 78: 1262-7
116. Dame C. Thrombopoietin in thrombocytopenias of childhood. Semin Thromb Hemost 2001; 27: 215-28
117. Jilma-Stohlawetz P, Homoncik M, Jilma B, Folman CC, von dem Borne AE, Bemaschek G, et al. High levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol 2001; 112: 466-8
118. Dame C, Fahnenstich H, Schaaff F, Schild R, Bartmann P. Longitudinal determinations of fetal thrombopoietin concentrations in severe Rhesus hemolytic disease (Abstract). Pediatr Res 2000; 47: 332A
119. Sekine I, Hagiwara T, Miyazaki H, Hirayama K, Dobashi H, Kogawa K, et al. Thrombocytopenia with absent radii syndrome: Studies on serum thrombopoietin levels and megakaryopoiesis in vitro. J Pediatr Hematol Oncol 1998; 20: 74-8
120. Al-Jefri AH, Dror Y, Bussel JB, Freedman MH. Thrombocytopenia with absent radii: Frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. Pediatr Hematol Oncol 2000; 17: 299-306
121. Letestu R, Vitrat N, Masse A, Le Couedic JP, Lazar V, Rameau P, et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000; 95: 1633-41
122. Strippoli P, Savoia A, Iolascon A, Tonelli R, Savino M, Giordano P, et al. Mutational screening of thrombopoietin receptor gene (c-mpl) in patients with congenital thrombocytopenia and absent radii (TAR). Br J Haematol 1998; 103: 311-4
123. Hedberg VA, Lipton JM. Thrombocytopenia with absent radii. A review of 100 cases. Am J Pediatr Hematol Oncol 1988; 10: 51-64
124. Muraoka K, Ishii E, Tsuji K, Yamamoto S, Yamaguchi H, Hara T, et al. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 1997; 96: 287-92
125. Van Den Oudenrijn S, Bruin M, Folman CC, Peters M, Faulkner LB, De Haas M, et al. Mutations in the thrombopoietin receptor, mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110: 441-8
126. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999; 96: 3132-6
127. Schwab M, Niemeyer C, Schwarzer U. Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. Med Pediatr Oncol 1998; 31: 159-65
128. Ruchelli ED, Uri A, Dimmick JE, Bove KE, Huff DS, Duncan LM, et al. Severe perinatal liver disease and Down syndrome: An apparent relationship. Hum Pathol 1991; 22: 1274-80
129. Ganick DJ. Hematological changes in Down's syndrome. Crit Rev Oncol Hematol 1986; 6: 55-69
130. Bonno M, Azuma E, Kawasaki H, Zhang XL, Komada Y, Hirayama M, et al. Thrombopoietin level is inversely related to blast count, not platelet number, in Down syndrome neonates with transient myeloproliferative disorder. Am J Hematol 1998; 58: 267-72
131. Colarizi P, Fiorucci P, Roggini M, Papoff P. Circulating thrombopoietin levels in a neonate with osteopetrosis. Pediatrics 1999; 103: 700-1
132. Warwick RM, Vaughan J, Murray N, Lubenko A, Roberts I. In vitro culture of colony forming unit-megakaryocyte (CFU-MK) in fetal alloimmune thrombocytopenia. Br J Haematol 1994; 88: 874-7
133. Chessells JM, Wigglesworth JS. Haemostatic failure in babies with rhesus isoimmunization. Arch Dis Child 1971; 46: 38-45
134. Koenig JM, Christensen RD. Neutropenia and thrombocytopenia in infants with Rh hemolytic disease. J Pediatr 1989; 114: 625-31
135. Saade GR, Moise KJ, Jr, Copel JA, Belfort MA, Carpenter RJ, Jr. Fetal platelet counts correlate with the severity of the anemia in red-cell alloimmunization. Obstet Gynecol 1993; 82: 987-91
136. Nicolini U, Nicolaidis P, Tannirandorn Y, Fisk NM, Nasrat H, Rodeck CH. Fetal liver dysfunction in Rh alloimmunization. Br J Obstet Gynaecol 1991; 98: 287-93
137. Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 1999; 29: 1739-42
138. Paul DA, Leef KH, Taylor S, McKenzie S. Thrombopoietin in preterm infants: Gestational age-dependent response. J Pediatr Hematol Oncol 2002; 24: 304-9
139. Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D, et al. Platelet transfusions in the neonatal intensive care unit: Factors predicting which patients will require multiple transfusions. Transfusion 2001; 41: 803-8
140. Sola MC, Christensen RD, Hutson AD, Tarantal AF. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000; 47: 208-14
141. Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996; 93: 783-8
142. Kato T, Matsumoto A, Ogami K, Tahara T, Morita H, Miyazaki H. Native thrombopoietin: Structure and function. Stem Cells 1998; 16: 322-8